Bayer AG / Vividion Therapeutics, Inc.

Oncology and immunology — small-molecule discovery via chemoproteomics platform targeting traditionally undruggable proteins

1.9M US cases/yr · $300.0B Combined global oncology + immunology drug market 2021 (USD MM, IQVIA) · 700 Approximate # human proteins successfully drugged historically (vs ~20,000 total proteins)

Disease Overview

Bayer's $2.0 billion acquisition of Vividion Therapeutics is best understood as a platform deal targeting two large therapeutic areas — oncology and immunology — where Vividion's chemoproteomics technology unlocked previously undruggable protein targets. The 2021 oncology drug market was approximately $186 billion globally, growing at 11-12% CAGR, with US oncology spend of approximately $90 billion. The 2021 immunology and immunoinflammation market was approximately $115 billion globally, anchored by anti-TNF biologics (Humira, Enbrel, Remicade) and IL-17/IL-23 inhibitors. The combined oncology+immunology total addressable market exceeded $300 billion in 2021. Beyond market scale, the strategic value of chemoproteomics lies in target accessibility — historically only ~10% of human proteins (roughly 600-700 of ~20,000) had been successfully drugged, with 80% of approved drugs hitting fewer than 700 targets and the majority of disease-relevant proteins lacking druggable pockets. Vividion's covalent chemoproteomics platform interrogates the entire human proteome to identify cryptic ligand-binding sites on proteins traditionally classified as undruggable — including transcription factors, scaffolding proteins, and cysteine-deficient surfaces. The lead programs at deal date were a covalent NRF2 inhibitor (oncology), a covalent NRF2 activator (immunology/inflammation), and a small-molecule WRN helicase inhibitor for MSI-high cancers — all best-in-class or first-in-class differentiation potential.

Competitive Landscape

The chemoproteomics and covalent-drug-discovery competitive landscape includes platform companies and big-pharma internal programs. Direct platform competitors at deal date included Kymera Therapeutics (targeted protein degradation/PROTACs, IRAK4 KT-474, STAT3 KT-333), Arvinas (PROTACs ARV-110/471 androgen and estrogen receptor degraders), C4 Therapeutics (degraders), Nurix Therapeutics (BCL6 NX-2127), Frontier Medicines (covalent chemoproteomics — closest direct competitor), Erasca (RAS/MAPK), Mirati Therapeutics (KRAS G12C adagrasib), Amgen (KRAS G12C sotorasib/Lumakras, FDA-approved May 2021), Black Diamond Therapeutics (allosteric oncoprotein inhibitors), Relay Therapeutics (motion-based drug discovery), Schrodinger (computational platform), Plexium and Lycia. Big-pharma chemoproteomics groups include Pfizer/Array (covalent KRAS), Roche/Genentech (degrader chemistry), AbbVie (BCL2/MCL1), Bristol Myers Squibb (Celgene CELMoDs CC-92480, CC-220), Novartis (NIBR/Genome Sciences) and J&J (Nurix collaboration). Vividion's NRF2 program competed with Reata Pharmaceuticals' bardoxolone methyl (NRF2 activator, FDA CRL Feb 2022), Aclaris Therapeutics, and academic NRF2 modulator programs. WRN helicase competitors at the time were limited — IDEAYA Biosciences and academic programs from Sanger Institute represented the only direct precedents.